This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 969764 results found since Jan 2013.

Causes of death among persons with multiple sclerosis
Conclusions Among NARCOMS participants older age at enrollment, male sex and greater disability were associated with increased mortality risk. This cohort of MS subjects had a lower proportionate mortality from cardiovascular disease and cancer compared to the U.S. population.
Source: Multiple Sclerosis and Related Disorders - July 18, 2015 Category: Neurology Source Type: research

Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis
Conclusions: Motor dysfunction in MS has a complex substrate that cannot be ascribed to a single neuroimaging finding, but is the consequence of infratentorial and spinal cord damage, as well as damage in the CST.
Source: Neurology - July 20, 2015 Category: Neurology Authors: Daams, M., Steenwijk, M. D., Wattjes, M. P., Geurts, J. J. G., Uitdehaag, B. M. J., Tewarie, P. K., Balk, L. J., Pouwels, P. J. W., Killestein, J., Barkhof, F. Tags: MRI, Multiple sclerosis ARTICLE Source Type: research

Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US department of defense administrative claims database
Conclusions Rates of mortality and several comorbidities are higher in the MS versus non-MS cohort. Early recognition and management of comorbidities may reduce premature mortality and improve quality of life in patients with MS.
Source: Multiple Sclerosis and Related Disorders - August 19, 2015 Category: Neurology Source Type: research

Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure
Publication date: Available online 25 September 2015 Source:Multiple Sclerosis and Related Disorders Author(s): Alicia S Chua, Bonnie I Glanz, Anthony J Guarino, Sandra L Cook, Emily E Greeke, Grace E Little, Tanuja Chitnis, Brian C Healy Several patient-reported outcome (PRO) measures are commonly used in multiple sclerosis (MS) research, but the relationship among items across measures is uncertain. We proposed to evaluate the associations between items from a standard battery of PRO measures used in MS research and to develop a brief, reliable and valid instrument measure by combining these items into a single...
Source: Multiple Sclerosis and Related Disorders - September 25, 2015 Category: Neurology Source Type: research

Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics
Conclusions: Findings from this study support a call for uniform guidelines regarding disclosure of physician–industry relationships to prospective research participants for industry-sponsored clinical trials.
Source: Multiple Sclerosis - October 6, 2015 Category: Neurology Authors: Solomon, A. J., Klein, E. P., Corboy, J. R., Bernat, J. L. Tags: Original Research Papers Source Type: research

Patient-reported outcomes and disability in multiple sclerosis
In the 2-year, phase 3 CARE-MS II study (NCT00548405), alemtuzumab demonstrated superior clinical and patient-reported outcomes (PROs) over subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis patients who had inadequate efficacy response to prior therapy. To further evaluate the relationship between PROs and disability, Short-Form 36-Item (SF-36) survey physical component summary (PCS) and mental component summary (MCS), and Functional Assessment of Multiple Sclerosis (FAMS) scores were analysed against Expanded Disability Status Scale (EDSS) outcomes, adjusted for baseline characteristics and randomi...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Scolding, N., Wang, H., Liu, Y., Steinman, L. Tags: Immunology (including allergy), Multiple sclerosis Thur 21, Parallel session 5: Therapeutics Source Type: research

The ms-smart trial in secondary progressive multiple sclerosis: a multi-arm, multi-centre trial of neuroprotection
There is currently no treatment for secondary progressive multiple sclerosis (SPMS) which determines the majority of disability in multiple sclerosis. The MS-SMART trial is a multi-arm, multi-centre, phase 2 randomised trial for patients with SPMS. A total of 440 patients with progressing SPMS will be recruited in England and Scotland and randomised to one of 4 blinded arms: amiloride 5mg bd, riluzole 50mg bd, fluoxetine 20mg bd or placebo. These agents have been chosen after an extensive systematic review which has suggested putative neuroprotective properties. Patients will be followed up for 96 weeks with outcome data c...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Chataway, J., Chandran, S., Miller, D., Giovannoni, G., Wheeler-Kingshott, C., Pavitt, S., Stallard, N., Hawkins, C., Sharrack, B., for the MS-SMART trialists Tags: Immunology (including allergy), Multiple sclerosis, Stroke, Radiology, Radiology (diagnostics) Thur 21, Parallel session 5: Therapeutics Source Type: research

Multiple sclerosis patient-derived CSF induces transcriptional changes in proliferating oligodendrocyte progenitors
Conclusions: Despite evidence of morphological differentiation induced by exposure to CSF of PPMS patients, the overall transcriptional response elicited in cultured OPCs was consistent with the activation of an aberrant transcriptional programme.
Source: Multiple Sclerosis - October 29, 2015 Category: Neurology Authors: Haines, J. D., Vidaurre, O. G., Zhang, F., Riffo-Campos, A. L., Castillo, J., Casanova, B., Casaccia, P., Lopez-Rodas, G. Tags: Original Research Papers Source Type: research

Important Role of Mast Cells in Multiple Sclerosis
Publication date: Available online 11 November 2015 Source:Multiple Sclerosis and Related Disorders Author(s): P. Conti, D. Kempuraj Autoimmunity is a disease that occurs when the body tissue is attacked by its own immune system. Multiple sclerosis (MS) is an autoimmune illness which triggers neurological progressive and persistent functions. MS is associated with an abnormal B-cell response and upregulation of T-cell reactivity against a multitude of antigens. Mast cells are the first line of the innate immune system and act by degranulating and secreting chemical mediators and cytokines. Their participation on the ce...
Source: Multiple Sclerosis and Related Disorders - November 12, 2015 Category: Neurology Source Type: research

Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial
Conclusion DAC HYP 150mg improved HRQoL in patients with RRMS compared to placebo. The treatment benefit can be partially attributed to reduction in disease activity and attenuation of the adverse impact of relapse on HRQoL.
Source: Multiple Sclerosis and Related Disorders - February 3, 2016 Category: Neurology Source Type: research

The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain
Multiple sclerosis is a chronic inflammatory disease with primary demyelination and neurodegeneration in the central nervous system. In our study we analysed demyelination and neurodegeneration in a large series of multiple sclerosis brains and provide a map that displays the frequency of different brain areas to be affected by these processes. Demyelination in the cerebral cortex was related to inflammatory infiltrates in the meninges, which was pronounced in invaginations of the brain surface (sulci) and possibly promoted by low flow of the cerebrospinal fluid in these areas. Focal demyelinated lesions in the white matte...
Source: Brain - February 25, 2016 Category: Neurology Authors: Haider, L., Zrzavy, T., Hametner, S., Höftberger, R., Bagnato, F., Grabner, G., Trattnig, S., Pfeifenbring, S., Brück, W., Lassmann, H. Tags: Multiple Sclerosis/Neuroinflammation Original Articles Source Type: research

Effects of Pilates exercises on sensory interaction, postural control and fatigue in patients with multiple sclerosis
Conclusions Ten-week Pilates training is effective to improve sensory interaction and to decrease fatigue. Pilates exercises can be applied safely in ambulatory pwMS for enhance sensory interaction and balance and combat fatigue. More investigations are needed.
Source: Multiple Sclerosis and Related Disorders - March 21, 2016 Category: Neurology Source Type: research

Interferon-Beta Exposure During First Trimester in Women with Multiple Sclerosis - A Prospective Cohort Study from the German Multiple Sclerosis and Pregnancy Registry (S24.005)
Conclusion IFN-beta exposure during early pregnancy does not decrease the mean birth weight and does not lead to preterm birth. Other pregnancy outcomes were similar between the exposed and unexposed groups. Our study provides further reassurance that IFN-beta has not to be withdrawn before pregnancy in women with MS.Disclosure: Dr. Thiel has nothing to disclose. Dr. Menck has nothing to disclose. Dr. Elias-Hamp has received personal compensation for activities with Biogen Idec, Merck Serono, Bayer Healthcare, Almirall, Novartis, Teva, and Genzyme as a speaker. Dr. Gold has received research support from Bayer HealthCare, ...
Source: Neurology - February 7, 2016 Category: Neurology Authors: Thiel, S., Menck, S., Elias-Hamp, B., Gold, R., Hellwig, K. Tags: Clinical Outcomes and Treatment Strategies in Multiple Sclerosis Source Type: research

Novel Multiple Sclerosis Genetic Risk Factors Are Involved in Epigenetic Regulation (S37.006)
Conclusions: Our GWAS approach in a defined population with limited substructure allowed identification of associations not found in larger, more heterogeneous cohorts, and thus provides new clues to the pathogenesis of MS.Disclosure: Dr. Buck has nothing to disclose. Dr. Andlauer has nothing to disclose. Dr. Bayas has received personal compensation for activities with Merck Serono, Biogen-Idec, Novartis and Sanofi/Genzyme as a speaker/consultant. Dr. Berger has received research support from the German Migraine and Headache Society. Dr. Berthele has nothing to disclose. Dr. Binder has nothing to disclose. Dr. Dankwoski ha...
Source: Neurology - February 7, 2016 Category: Neurology Authors: Buck, D., Andlauer, T., Bayas, A., Berger, K., Berthele, A., Binder, E., Dankwoski, T., Franke, A., Gold, R., Herms, S., Homuth, G., Joeckel, K.-H., Kacprowski, T., Kieseier, B., Kuempfel, T., Laudes, M., Lieb, W., Limmroth, V., Linker, R., Moebus, S., Mu Tags: Risk Factors for Multiple Sclerosis Source Type: research

A Comparison of Two Methods for Quantifying Blood-Brain Barrier Disruption, with Application to Multiple Sclerosis (S45.006)
Conclusions: Dual-echo dynamic susceptibility contrast scanning is a clinically feasible approach for quantification of BBB changes in multiple sclerosis. When using single-echo T2*-weighted imaging to do permeability analysis, longer echo times will likely perform better than shorter echo times.Disclosure: Dr. Chen has nothing to disclose. Dr. Selvaganesan has nothing to disclose. Dr. Reich has received research support from Vertex Pharmaceuticals. Dr. Nair has nothing to disclose. Dr. Leigh has nothing to disclose.
Source: Neurology - February 7, 2016 Category: Neurology Authors: Chen, N., Selvaganesan, K., Reich, D., Nair, G., Leigh, R. Tags: MRI and OCT Outcomes in Multiple Sclerosis Source Type: research